Adimmune Corporation (4142.TW) TAI
Currency In TWD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In TWD
Address
No. 3, Tanxing Road
Taichung, 427003
Taiwan (Province of China)
Phone
886 4 2538 1220
Website
Sector
Healthcare
Industry
Biotechnology
Employees
564
First IPO Date
May 03, 2012
| Name | Title | Pay | Year Born |
| Chi-Hsien Chan | Chief Executive Officer & Chairman | 24.04M | N/A |
| Chin-I Chiu | Vice President of Quality Assurance Department | 5.13M | N/A |
| Fei Pan | Chief Legal Officer & General Counsel | 5.25M | N/A |
| Chin-Chuan Chang | Chief Operating Officer and Vice President of R&D | 5.34M | N/A |
| Zhe Wei Zhang | Executive Vice GM | 0 | N/A |
| Cheng Liu Churg | Acting R&D Officer | 0 | N/A |
| Chih-Hsiang Leng | Head of R&D Division | 0 | N/A |
| Li-Ya Tang | Director of Administration Center | 0 | N/A |
Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influenza vaccine, AdimFlu-S, alongside trivalent influenza vaccines and the Influenza A (H1N1) Virus Monovalent Vaccine. The company also provides tetanus toxoid products, vital for post-injury tetanus prevention, and Japanese encephalitis vaccines. Furthermore, Adimmune supplies purified Tuberculin and extends its expertise through contract manufacturing services. Established in 1965, the company initially operated under the name Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. It subsequently rebranded as Adimmune Corporation in 2001 and maintains its headquarters in Taichung, Taiwan.